VERSATIS

This brand name is authorized in Austria, Croatia, Ecuador, Estonia, France, Ireland, Lithuania, Mexico, Netherlands, Poland, Romania, South Africa, Spain, UK.

Active ingredients

The drug VERSATIS contains one active pharmaceutical ingredient (API):

1	Lidocaine UNII 98PI200987 - LIDOCAINE
	Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane.
	Read more about Lidocaine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N01BB02	Lidocaine	N Nervous system → N01 Anesthetics → N01B Anesthetics, local → N01BB Amides
Discover more medicines within N01BB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	27.909-12-07
EE	Ravimiamet	1433090, 1433102, 1433113, 1433124, 1433135
ES	Centro de información online de medicamentos de la AEMPS	34009, 3400938285673, 71848
FR	Base de données publique des médicaments	65538840
GB	Medicines & Healthcare Products Regulatory Agency	110527, 369026, 374472, 377083, 379738, 381731
HR	Agencija za lijekove i medicinske proizvode	HR-H-140669749
IE	Health Products Regulatory Authority	11020, 30500
LT	Valstybinė vaistų kontrolės tarnyba	1038830, 1058245, 1058246, 1058247, 1058248
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	166M
NL	Z-Index G-Standaard, PRK	83372
PL	Rejestru Produktów Leczniczych	100241048
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64546001, W64546002, W64546003, W64546004, W64546005
ZA	Health Products Regulatory Authority	43/3.2.3/0382